A review of the cutaneous toxicities of tebentafusp—Featuring two cases involving superficial bullous reactions
2022; Wiley; Volume: 63; Issue: 3 Linguagem: Inglês
10.1111/ajd.13866
ISSN1440-0960
AutoresJames P. Pham, Phoebe Star, Luke Ardolino, Annika Smith, Anthony M. Joshua,
Tópico(s)Nail Diseases and Treatments
ResumoAustralasian Journal of DermatologyVolume 63, Issue 3 p. e279-e282 CLINICAL LETTER A review of the cutaneous toxicities of tebentafusp—Featuring two cases involving superficial bullous reactions James P. Pham MD, Corresponding Author James P. Pham MD [email protected] orcid.org/0000-0002-9263-3889 St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia Correspondence James Pham, St. Vincent's Hospital, 390 Victoria St, Darlinghurst, NSW 2010, Australia. Email: [email protected]Search for more papers by this authorPhoebe Star MBBS, MPhil, Phoebe Star MBBS, MPhil orcid.org/0000-0001-5746-9799 St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, AustraliaSearch for more papers by this authorLuke Ardolino MBChB, Luke Ardolino MBChB orcid.org/0000-0002-8998-7141 St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia Department of Medical Oncology, The Kinghorn Cancer Centre, Darlinghurst, New South Wales, AustraliaSearch for more papers by this authorAnnika Smith MBBS, MPH, TM, Annika Smith MBBS, MPH, TM orcid.org/0000-0001-9520-920X St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia Melanoma Institute of Australia, New South Wales, AustraliaSearch for more papers by this authorAnthony M. Joshua MBBS, PhD, Anthony M. Joshua MBBS, PhD orcid.org/0000-0001-5159-4580 St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia Department of Medical Oncology, The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia Melanoma Institute of Australia, New South Wales, AustraliaSearch for more papers by this author James P. Pham MD, Corresponding Author James P. Pham MD [email protected] orcid.org/0000-0002-9263-3889 St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia Correspondence James Pham, St. Vincent's Hospital, 390 Victoria St, Darlinghurst, NSW 2010, Australia. Email: [email protected]Search for more papers by this authorPhoebe Star MBBS, MPhil, Phoebe Star MBBS, MPhil orcid.org/0000-0001-5746-9799 St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, AustraliaSearch for more papers by this authorLuke Ardolino MBChB, Luke Ardolino MBChB orcid.org/0000-0002-8998-7141 St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia Department of Medical Oncology, The Kinghorn Cancer Centre, Darlinghurst, New South Wales, AustraliaSearch for more papers by this authorAnnika Smith MBBS, MPH, TM, Annika Smith MBBS, MPH, TM orcid.org/0000-0001-9520-920X St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia Melanoma Institute of Australia, New South Wales, AustraliaSearch for more papers by this authorAnthony M. Joshua MBBS, PhD, Anthony M. Joshua MBBS, PhD orcid.org/0000-0001-5159-4580 St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia Department of Medical Oncology, The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia Melanoma Institute of Australia, New South Wales, AustraliaSearch for more papers by this author First published: 05 May 2022 https://doi.org/10.1111/ajd.13866Citations: 1Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES 1Nathan P, Hassel JC, Rutkowski P, Baurain J-F, Butler MO, Schlaak M, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021; 385(13): 1196– 206. https://doi.org/10.1056/NEJMoa2103485 2Middleton MR, McAlpine C, Woodcock VK, Corrie P, Infante JR, Steven NM, et al. Tebentafusp, a TCR/anti-cd3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res. 2020; 26(22): 5869– 78. https://doi.org/10.1158/1078-0432.CCR-20-1247 3 FDA approves tebentafusp-tebn for unresectable or metastatic uveal melanoma. (2022). Retrieved 28 March 2022, from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approves-tebentafusp-tebn-unresectable-or-metastatic-uveal-melanoma 4Orloff M, Sacco JJ, Nathan P, Holland C, Cohen C, Harper J, et al. Vitiligo and other clinical melanocyte-related adverse events following tebentafusp (IMCgp100) exposure in patients with uveal melanoma. Cancer Res. 2020; 80(16_Supplement). https://doi.org/10.1158/1538-7445.AM2020-3295 5Ritprajak P, Azuma M. Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol. 2015; 51(3): 221– 8. https://doi.org/10.1016/j.oraloncology.2014.11.014 6La-Beck NM, Jean GW, Huynh C, Alzghari SK, Lowe DB. Immune checkpoint inhibitors: new insights and current place in cancer therapy. Pharmacotherapy. 2015; 35(10): 963– 76. https://doi.org/10.1002/phar.1643 7Hassel JC, Rutkowski P, Baurain J-F, Butler MO, Schlaak M, Sullivan R, et al. Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator's choice (IC) in first-line metastatic uveal melanoma. J Clin Oncol. 2021; 39: 9527. Citing Literature Volume63, Issue3August 2022Pages e279-e282 ReferencesRelatedInformation
Referência(s)